Last reviewed · How we verify

Arbeitsgemeinschaft medikamentoese Tumortherapie — Portfolio Competitive Intelligence Brief

Arbeitsgemeinschaft medikamentoese Tumortherapie pipeline: 1 marketed, 0 filed, 2 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 4 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Vincristin Vincristin marketed Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1 Oncology
Dronabinol in Oral Dosage Form Dronabinol in Oral Dosage Form phase 3 Cannabinoid receptor agonist CB1 receptor, CB2 receptor Oncology
Placebo in Oral Dosage Form Placebo in Oral Dosage Form phase 3

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Hoffmann-La Roche · 2 shared drug classes
  2. Amgen · 1 shared drug class
  3. Baxalta now part of Shire · 1 shared drug class
  4. Association pour la Recherche sur le Temps Biologique et la Chronothérapie · 1 shared drug class
  5. AstraZeneca · 1 shared drug class
  6. Azienda Ospedaliera Universitaria Integrata Verona · 1 shared drug class
  7. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  8. Alexion Pharmaceuticals, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Arbeitsgemeinschaft medikamentoese Tumortherapie:

Cite this brief

Drug Landscape (2026). Arbeitsgemeinschaft medikamentoese Tumortherapie — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/arbeitsgemeinschaft-medikamentoese-tumortherapie. Accessed 2026-05-17.

Related